Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition

Background In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown that growth hormone is also beneficial for adults with PWS, improving body composition. However, little is known about the longer-term effects....

Full description

Saved in:

Bibliographic Details
Published in:	Orphanet journal of rare diseases Vol. 15; no. 1; pp. 1 - 9
Main Authors:	Damen, Layla, Donze, Stephany H., Kuppens, Renske J., Bakker, Nienke E., de Graaff, Laura C. G., van der Velden, Janielle A. E. M., Hokken-Koelega, Anita C. S.
Format:	Journal Article
Language:	English
Published:	London BioMed Central 24.06.2020 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Adults Age Blood pressure Body composition Body fat Body mass Body mass index Care and treatment Children Drug dosages Dual energy X-ray absorptiometry Glucose Growth hormone Growth hormones Human Genetics Insulin Lean body mass Medical research Medicine Medicine & Public Health Pharmacology/Toxicology Physical growth Physiological aspects Prader Willi syndrome Rare diseases Rare endocrinological diseases Somatotropin Studies Young adults Youth Netherlands Adults Prader Willi syndrome Growth hormone Body composition
ISSN:	1750-1172, 1750-1172
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Background In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown that growth hormone is also beneficial for adults with PWS, improving body composition. However, little is known about the longer-term effects. This study investigated the effects on body composition in adult patients with PWS during 3 years of growth hormone therapy in a dose of 0.33 mg/m 2 /day. Methods Open-label, prospective study in 43 young adults with PWS with a median (IQR) age of 19.0 (17.5 to 20.7) years. Fat mass percentage SDS and lean body mass SDS were measured annually by DXA. Results Estimated mean (95% CI) fat mass percentage SDS decreased during the three-year study from 2.1 (1.9 to 2.3) SDS at start to 1.9 (1.8 to 2.1) SDS, p = 0.012, while lean body mass SDS remained stable at − 2.1 (− 2.4 to − 1.8) SDS at start to − 1.9 (− 2.3 to − 1.6) after 3 years, p = 0.15. Fasting glucose and insulin remained similar during the three-year study, glucose being 4.6 (4.4 to 4.8) mmol/l at start and 4.6 (4.5 to 4.7) mmol/l after 3 years of growth hormone, p = 0.93 and insulin being 59.5 (42.2 to 81.5) pmol/l and 55.0 (42.4 to 69.2) pmol/l, resp., p = 0.54. There were no growth hormone-related adverse events during the study. Conclusions Three years of growth hormone treatment in young adults with PWS maintains the positive effects on body composition attained during childhood. Thus, adults with PWS benefit from longer-term growth hormone treatment. Trial registration EudraCT, EudraCT number 2011-001313-14 . Registered 17 October 2012.
AbstractList	Background In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown that growth hormone is also beneficial for adults with PWS, improving body composition. However, little is known about the longer-term effects. This study investigated the effects on body composition in adult patients with PWS during 3 years of growth hormone therapy in a dose of 0.33 mg/m.sup.2/day. Methods Open-label, prospective study in 43 young adults with PWS with a median (IQR) age of 19.0 (17.5 to 20.7) years. Fat mass percentage SDS and lean body mass SDS were measured annually by DXA. Results Estimated mean (95% CI) fat mass percentage SDS decreased during the three-year study from 2.1 (1.9 to 2.3) SDS at start to 1.9 (1.8 to 2.1) SDS, p = 0.012, while lean body mass SDS remained stable at - 2.1 (- 2.4 to - 1.8) SDS at start to - 1.9 (- 2.3 to - 1.6) after 3 years, p = 0.15. Fasting glucose and insulin remained similar during the three-year study, glucose being 4.6 (4.4 to 4.8) mmol/l at start and 4.6 (4.5 to 4.7) mmol/l after 3 years of growth hormone, p = 0.93 and insulin being 59.5 (42.2 to 81.5) pmol/l and 55.0 (42.4 to 69.2) pmol/l, resp., p = 0.54. There were no growth hormone-related adverse events during the study. Conclusions Three years of growth hormone treatment in young adults with PWS maintains the positive effects on body composition attained during childhood. Thus, adults with PWS benefit from longer-term growth hormone treatment. Trial registration EudraCT, EudraCT number 2011-001313-14. Registered 17 October 2012. Keywords: Prader Willi syndrome, Adults, Body composition, Growth hormone Background In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown that growth hormone is also beneficial for adults with PWS, improving body composition. However, little is known about the longer-term effects. This study investigated the effects on body composition in adult patients with PWS during 3 years of growth hormone therapy in a dose of 0.33 mg/m2/day. Methods Open-label, prospective study in 43 young adults with PWS with a median (IQR) age of 19.0 (17.5 to 20.7) years. Fat mass percentage SDS and lean body mass SDS were measured annually by DXA. Results Estimated mean (95% CI) fat mass percentage SDS decreased during the three-year study from 2.1 (1.9 to 2.3) SDS at start to 1.9 (1.8 to 2.1) SDS, p = 0.012, while lean body mass SDS remained stable at − 2.1 (− 2.4 to − 1.8) SDS at start to − 1.9 (− 2.3 to − 1.6) after 3 years, p = 0.15. Fasting glucose and insulin remained similar during the three-year study, glucose being 4.6 (4.4 to 4.8) mmol/l at start and 4.6 (4.5 to 4.7) mmol/l after 3 years of growth hormone, p = 0.93 and insulin being 59.5 (42.2 to 81.5) pmol/l and 55.0 (42.4 to 69.2) pmol/l, resp., p = 0.54. There were no growth hormone-related adverse events during the study. Conclusions Three years of growth hormone treatment in young adults with PWS maintains the positive effects on body composition attained during childhood. Thus, adults with PWS benefit from longer-term growth hormone treatment. Trial registration EudraCT, EudraCT number 2011-001313-14. Registered 17 October 2012. In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown that growth hormone is also beneficial for adults with PWS, improving body composition. However, little is known about the longer-term effects. This study investigated the effects on body composition in adult patients with PWS during 3 years of growth hormone therapy in a dose of 0.33 mg/m2/day.BACKGROUNDIn children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown that growth hormone is also beneficial for adults with PWS, improving body composition. However, little is known about the longer-term effects. This study investigated the effects on body composition in adult patients with PWS during 3 years of growth hormone therapy in a dose of 0.33 mg/m2/day.Open-label, prospective study in 43 young adults with PWS with a median (IQR) age of 19.0 (17.5 to 20.7) years. Fat mass percentage SDS and lean body mass SDS were measured annually by DXA.METHODSOpen-label, prospective study in 43 young adults with PWS with a median (IQR) age of 19.0 (17.5 to 20.7) years. Fat mass percentage SDS and lean body mass SDS were measured annually by DXA.Estimated mean (95% CI) fat mass percentage SDS decreased during the three-year study from 2.1 (1.9 to 2.3) SDS at start to 1.9 (1.8 to 2.1) SDS, p = 0.012, while lean body mass SDS remained stable at - 2.1 (- 2.4 to - 1.8) SDS at start to - 1.9 (- 2.3 to - 1.6) after 3 years, p = 0.15. Fasting glucose and insulin remained similar during the three-year study, glucose being 4.6 (4.4 to 4.8) mmol/l at start and 4.6 (4.5 to 4.7) mmol/l after 3 years of growth hormone, p = 0.93 and insulin being 59.5 (42.2 to 81.5) pmol/l and 55.0 (42.4 to 69.2) pmol/l, resp., p = 0.54. There were no growth hormone-related adverse events during the study.RESULTSEstimated mean (95% CI) fat mass percentage SDS decreased during the three-year study from 2.1 (1.9 to 2.3) SDS at start to 1.9 (1.8 to 2.1) SDS, p = 0.012, while lean body mass SDS remained stable at - 2.1 (- 2.4 to - 1.8) SDS at start to - 1.9 (- 2.3 to - 1.6) after 3 years, p = 0.15. Fasting glucose and insulin remained similar during the three-year study, glucose being 4.6 (4.4 to 4.8) mmol/l at start and 4.6 (4.5 to 4.7) mmol/l after 3 years of growth hormone, p = 0.93 and insulin being 59.5 (42.2 to 81.5) pmol/l and 55.0 (42.4 to 69.2) pmol/l, resp., p = 0.54. There were no growth hormone-related adverse events during the study.Three years of growth hormone treatment in young adults with PWS maintains the positive effects on body composition attained during childhood. Thus, adults with PWS benefit from longer-term growth hormone treatment.CONCLUSIONSThree years of growth hormone treatment in young adults with PWS maintains the positive effects on body composition attained during childhood. Thus, adults with PWS benefit from longer-term growth hormone treatment.EudraCT, EudraCT number 2011-001313-14. Registered 17 October 2012.TRIAL REGISTRATIONEudraCT, EudraCT number 2011-001313-14. Registered 17 October 2012. In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown that growth hormone is also beneficial for adults with PWS, improving body composition. However, little is known about the longer-term effects. Open-label, prospective study in 43 young adults with PWS with a median (IQR) age of 19.0 (17.5 to 20.7) years. Fat mass percentage SDS and lean body mass SDS were measured annually by DXA. Estimated mean (95% CI) fat mass percentage SDS decreased during the three-year study from 2.1 (1.9 to 2.3) SDS at start to 1.9 (1.8 to 2.1) SDS, p = 0.012, while lean body mass SDS remained stable at - 2.1 (- 2.4 to - 1.8) SDS at start to - 1.9 (- 2.3 to - 1.6) after 3 years, p = 0.15. Fasting glucose and insulin remained similar during the three-year study, glucose being 4.6 (4.4 to 4.8) mmol/l at start and 4.6 (4.5 to 4.7) mmol/l after 3 years of growth hormone, p = 0.93 and insulin being 59.5 (42.2 to 81.5) pmol/l and 55.0 (42.4 to 69.2) pmol/l, resp., p = 0.54. There were no growth hormone-related adverse events during the study. Three years of growth hormone treatment in young adults with PWS maintains the positive effects on body composition attained during childhood. Thus, adults with PWS benefit from longer-term growth hormone treatment. Abstract Background In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown that growth hormone is also beneficial for adults with PWS, improving body composition. However, little is known about the longer-term effects. This study investigated the effects on body composition in adult patients with PWS during 3 years of growth hormone therapy in a dose of 0.33 mg/m2/day. Methods Open-label, prospective study in 43 young adults with PWS with a median (IQR) age of 19.0 (17.5 to 20.7) years. Fat mass percentage SDS and lean body mass SDS were measured annually by DXA. Results Estimated mean (95% CI) fat mass percentage SDS decreased during the three-year study from 2.1 (1.9 to 2.3) SDS at start to 1.9 (1.8 to 2.1) SDS, p = 0.012, while lean body mass SDS remained stable at − 2.1 (− 2.4 to − 1.8) SDS at start to − 1.9 (− 2.3 to − 1.6) after 3 years, p = 0.15. Fasting glucose and insulin remained similar during the three-year study, glucose being 4.6 (4.4 to 4.8) mmol/l at start and 4.6 (4.5 to 4.7) mmol/l after 3 years of growth hormone, p = 0.93 and insulin being 59.5 (42.2 to 81.5) pmol/l and 55.0 (42.4 to 69.2) pmol/l, resp., p = 0.54. There were no growth hormone-related adverse events during the study. Conclusions Three years of growth hormone treatment in young adults with PWS maintains the positive effects on body composition attained during childhood. Thus, adults with PWS benefit from longer-term growth hormone treatment. Trial registration EudraCT, EudraCT number 2011-001313-14 . Registered 17 October 2012. Background In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown that growth hormone is also beneficial for adults with PWS, improving body composition. However, little is known about the longer-term effects. This study investigated the effects on body composition in adult patients with PWS during 3 years of growth hormone therapy in a dose of 0.33 mg/m 2 /day. Methods Open-label, prospective study in 43 young adults with PWS with a median (IQR) age of 19.0 (17.5 to 20.7) years. Fat mass percentage SDS and lean body mass SDS were measured annually by DXA. Results Estimated mean (95% CI) fat mass percentage SDS decreased during the three-year study from 2.1 (1.9 to 2.3) SDS at start to 1.9 (1.8 to 2.1) SDS, p = 0.012, while lean body mass SDS remained stable at − 2.1 (− 2.4 to − 1.8) SDS at start to − 1.9 (− 2.3 to − 1.6) after 3 years, p = 0.15. Fasting glucose and insulin remained similar during the three-year study, glucose being 4.6 (4.4 to 4.8) mmol/l at start and 4.6 (4.5 to 4.7) mmol/l after 3 years of growth hormone, p = 0.93 and insulin being 59.5 (42.2 to 81.5) pmol/l and 55.0 (42.4 to 69.2) pmol/l, resp., p = 0.54. There were no growth hormone-related adverse events during the study. Conclusions Three years of growth hormone treatment in young adults with PWS maintains the positive effects on body composition attained during childhood. Thus, adults with PWS benefit from longer-term growth hormone treatment. Trial registration EudraCT, EudraCT number 2011-001313-14 . Registered 17 October 2012.
ArticleNumber	163
Audience	Academic
Author	Donze, Stephany H. Damen, Layla Hokken-Koelega, Anita C. S. Kuppens, Renske J. van der Velden, Janielle A. E. M. de Graaff, Laura C. G. Bakker, Nienke E.
Author_xml	– sequence: 1 givenname: Layla orcidid: 0000-0003-2562-6176 surname: Damen fullname: Damen, Layla email: l.damen@kindengroei.nl organization: Dutch Growth Research Foundation, Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children’s Hospital – sequence: 2 givenname: Stephany H. surname: Donze fullname: Donze, Stephany H. organization: Dutch Growth Research Foundation, Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children’s Hospital – sequence: 3 givenname: Renske J. surname: Kuppens fullname: Kuppens, Renske J. organization: Dutch Growth Research Foundation, Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children’s Hospital – sequence: 4 givenname: Nienke E. surname: Bakker fullname: Bakker, Nienke E. organization: Dutch Growth Research Foundation, Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children’s Hospital – sequence: 5 givenname: Laura C. G. surname: de Graaff fullname: de Graaff, Laura C. G. organization: Internal Medicine, Division of Endocrinology, Erasmus University Medical Center – sequence: 6 givenname: Janielle A. E. M. surname: van der Velden fullname: van der Velden, Janielle A. E. M. organization: Department of Pediatrics, Subdivision of Endocrinology, Radboud University Medical Center-Amalia Children’s Hospital – sequence: 7 givenname: Anita C. S. surname: Hokken-Koelega fullname: Hokken-Koelega, Anita C. S. organization: Dutch Growth Research Foundation, Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children’s Hospital
BookMark	eNp9kktv1DAUhSNURB_wB1hZYkMXKX4kjssCqap4jFQJBEUsLce-zniU2MV2WmbLL8fTqShToSoLR9ffOde-PofVng8equolwSeECP4mEYYpqzHFNSZNg2v-pDogXYtrQjq698__fnWY0grjpmVYPKv2GW0F7jpxUP2-XEYAtAYVEwoWDTHc5CVahjiVZihHUHkCn5HzaB1mPyBl5jEndOMK9iUqA7H-4cbRobT2JoYJ3qI0p6ycB4OuQnLZXQMCa0EXWfCoD2aNdJi2e8E_r55aNSZ4cbceVd8_vL88_1RffP64OD-7qDUnIte9AaMIMAwgLGkIoQaTTquWm1ML3PaKt6blgAXuRU9LFXpjWwW2B640sKNqsfU1Qa3kVXSTimsZlJO3hRAHqWJ2egQJbQsaa0wI7hvWNYoZobDmtCMUNxYXr3dbr6u5n8DoMqGoxh3T3R3vlnII17JjhBHCisHrO4MYfs6Qspxc0jCOykOYk6QN6ZggZSnoqwfoKszRl1EVijYdP6WC3VODKhdw3obSV29M5RmnAhPWNhvq5D9U-QxMTpcXt67UdwTHO4LCZPiVBzWnJBffvu6ydMvqGFKKYP_Og2C5SazcJlaWxMrbxEpeROKBSLusNrkoJ3Pj41K2labSxw8Q7wfziOoPCLAB2w
CitedBy_id	crossref_primary_10_1016_j_metabol_2022_155295 crossref_primary_10_1111_cen_14274 crossref_primary_10_1159_000530420 crossref_primary_10_1016_S2213_8587_21_00002_4 crossref_primary_10_1007_s13679_022_00478_w crossref_primary_10_1515_jpem_2024_0408 crossref_primary_10_2147_AHMT_S214893 crossref_primary_10_1186_s13023_020_01651_x crossref_primary_10_1210_clinem_dgab406 crossref_primary_10_3390_jcm11144033 crossref_primary_10_1055_a_2606_2353 crossref_primary_10_3390_jcm10153250 crossref_primary_10_1016_j_obpill_2024_100139 crossref_primary_10_1210_clinem_dgac082 crossref_primary_10_2147_DDDT_S440009
Cites_doi	10.1210/jc.2013-3059 10.1210/jc.2013-2012 10.1352/1944-7558-120.4.315 10.1111/j.1365-2265.2007.03126.x 10.1038/oby.2006.193 10.1210/jc.2007-2212 10.1038/ejhg.2008.165 10.1210/jc.2009-1389 10.1111/j.1651-2227.2000.tb00755.x 10.1210/jc.2008-0649 10.1542/peds.91.2.398 10.1016/j.ghir.2013.01.001 10.1016/j.ridd.2013.05.024 10.1093/ajcn/66.2.232 10.1046/j.1365-2265.2003.01769.x 10.1016/j.ghir.2011.05.002 10.1210/jc.2016-2594 10.1203/00006450-200003000-00006 10.1210/jc.2012-3888 10.1038/oby.2004.241 10.1210/jc.2010-0907 10.1136/adc.82.2.107 10.1007/BF03349255 10.1136/jmg.34.11.917 10.1093/ajcn/65.5.1369 10.1210/jc.2012-2881 10.1067/S0022-3476(03)00386-X 10.1210/jc.2009-0454 10.1210/jc.2012-1182
ContentType	Journal Article
Copyright	The Author(s) 2020 COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION ISR 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AN0 AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.1186/s13023-020-01440-6
DatabaseName	Springer Nature OA Free Journals CrossRef Gale In Context: Science ProQuest Central (Corporate) Immunology Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Open Access: DOAJ - Directory of Open Access Journals
DatabaseTitle	CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1750-1172
EndPage	9
ExternalDocumentID	oai_doaj_org_article_e55ec0c0110b4374a3d8a0c6271204f0 PMC7313113 A628013543 10_1186_s13023_020_01440_6
GeographicLocations	Netherlands
GeographicLocations_xml	– name: Netherlands
GrantInformation_xml	– fundername: Pfizer Pharmaceuticals grantid: N/A funderid: http://dx.doi.org/10.13039/100014476 – fundername: ; grantid: N/A
GroupedDBID	--- 0R~ 123 29N 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ISR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c618t-bdeda1e30ee8f14112d017ca56d9fe6fba65d56e080b8b26d9ebdf5aefbe6ace3
IEDL.DBID	7X7
ISICitedReferencesCount	19
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000544983900003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1750-1172
IngestDate	Mon Nov 10 04:34:40 EST 2025 Tue Nov 04 01:51:22 EST 2025 Fri Sep 05 13:20:26 EDT 2025 Sun Oct 19 01:28:57 EDT 2025 Tue Nov 11 10:03:25 EST 2025 Tue Nov 04 17:36:39 EST 2025 Thu Nov 13 15:33:56 EST 2025 Sat Nov 29 03:40:40 EST 2025 Tue Nov 18 20:15:40 EST 2025 Sat Sep 06 07:29:06 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Adults Prader Willi syndrome Growth hormone Body composition
Language	English
License	Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c618t-bdeda1e30ee8f14112d017ca56d9fe6fba65d56e080b8b26d9ebdf5aefbe6ace3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0003-2562-6176
OpenAccessLink	https://www.proquest.com/docview/2424769283?pq-origsite=%requestingapplication%
PMID	32580778
PQID	2424769283
PQPubID	76088
PageCount	9
ParticipantIDs	doaj_primary_oai_doaj_org_article_e55ec0c0110b4374a3d8a0c6271204f0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7313113 proquest_miscellaneous_2417381241 proquest_journals_2424769283 gale_infotracmisc_A628013543 gale_infotracacademiconefile_A628013543 gale_incontextgauss_ISR_A628013543 crossref_primary_10_1186_s13023_020_01440_6 crossref_citationtrail_10_1186_s13023_020_01440_6 springer_journals_10_1186_s13023_020_01440_6
PublicationCentury	2000
PublicationDate	2020-06-24
PublicationDateYYYYMMDD	2020-06-24
PublicationDate_xml	– month: 06 year: 2020 text: 2020-06-24 day: 24
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London
PublicationTitle	Orphanet journal of rare diseases
PublicationTitleAbbrev	Orphanet J Rare Dis
PublicationYear	2020
Publisher	BioMed Central BioMed Central Ltd Springer Nature B.V BMC
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC
References	CL Deal (1440_CR29) 2013; 98 AL Carrel (1440_CR13) 2010; 95 ST Lo (1440_CR11) 2015; 120 HR Mogul (1440_CR19) 2008; 93 ST Lo (1440_CR10) 2013; 34 RF de Lind van Wijngaarden (1440_CR21) 2009; 94 RJ Kuppens (1440_CR14) 2016; 101 P Brambilla (1440_CR7) 1997; 65 B Rikken (1440_CR28) 1998; 50 AP Goldstone (1440_CR2) 2008; 93 R Sode-Carlsen (1440_CR20) 2011; 21 AM Fredriks (1440_CR22) 2000; 47 AM Fredriks (1440_CR23) 2000; 82 M Bidlingmaier (1440_CR27) 2014; 99 NE Bakker (1440_CR5) 2013; 98 MT Bekx (1440_CR6) 2003; 143 DA Festen (1440_CR8) 2008; 68 C Hoybye (1440_CR15) 2003; 58 BP Hauffa (1440_CR24) 2000; 89 VA Holm (1440_CR3) 1993; 91 EP Siemensma (1440_CR9) 2012; 97 SB Cassidy (1440_CR1) 2009; 17 MG Butler (1440_CR17) 2013; 23 LA Gondoni (1440_CR18) 2008; 31 Y Guo (1440_CR25) 2004; 12 R Sode-Carlsen (1440_CR16) 2010; 95 M Coupaye (1440_CR12) 2013; 98 AM Boot (1440_CR26) 1997; 66 MF Theodoro (1440_CR30) 2006; 14 SB Cassidy (1440_CR4) 1997; 34
References_xml	– volume: 99 start-page: 1712 issue: 5 year: 2014 ident: 1440_CR27 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2013-3059 – volume: 98 start-page: 4013 issue: 10 year: 2013 ident: 1440_CR5 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2013-2012 – volume: 120 start-page: 315 issue: 4 year: 2015 ident: 1440_CR11 publication-title: Am J Intellect Dev Disabil doi: 10.1352/1944-7558-120.4.315 – volume: 68 start-page: 919 issue: 6 year: 2008 ident: 1440_CR8 publication-title: Clin Endocrinol doi: 10.1111/j.1365-2265.2007.03126.x – volume: 14 start-page: 1685 issue: 10 year: 2006 ident: 1440_CR30 publication-title: Obesity (Silver Spring) doi: 10.1038/oby.2006.193 – volume: 93 start-page: 1238 issue: 4 year: 2008 ident: 1440_CR19 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2007-2212 – volume: 17 start-page: 3 issue: 1 year: 2009 ident: 1440_CR1 publication-title: Eur J Hum Genet doi: 10.1038/ejhg.2008.165 – volume: 95 start-page: 1131 issue: 3 year: 2010 ident: 1440_CR13 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2009-1389 – volume: 89 start-page: 1302 issue: 11 year: 2000 ident: 1440_CR24 publication-title: Acta Paediatr doi: 10.1111/j.1651-2227.2000.tb00755.x – volume: 93 start-page: 4183 issue: 11 year: 2008 ident: 1440_CR2 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2008-0649 – volume: 91 start-page: 398 issue: 2 year: 1993 ident: 1440_CR3 publication-title: Pediatrics doi: 10.1542/peds.91.2.398 – volume: 23 start-page: 81 issue: 3 year: 2013 ident: 1440_CR17 publication-title: Growth Hormon IGF Res doi: 10.1016/j.ghir.2013.01.001 – volume: 50 start-page: 166 issue: 3 year: 1998 ident: 1440_CR28 publication-title: Horm Res – volume: 34 start-page: 2764 issue: 9 year: 2013 ident: 1440_CR10 publication-title: Res Dev Disabil doi: 10.1016/j.ridd.2013.05.024 – volume: 66 start-page: 232 issue: 2 year: 1997 ident: 1440_CR26 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/66.2.232 – volume: 58 start-page: 653 issue: 5 year: 2003 ident: 1440_CR15 publication-title: Clin Endocrinol doi: 10.1046/j.1365-2265.2003.01769.x – volume: 21 start-page: 185 issue: 4 year: 2011 ident: 1440_CR20 publication-title: Growth Hormon IGF Res doi: 10.1016/j.ghir.2011.05.002 – volume: 101 start-page: 4110 issue: 11 year: 2016 ident: 1440_CR14 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2016-2594 – volume: 47 start-page: 316 issue: 3 year: 2000 ident: 1440_CR22 publication-title: Pediatr Res doi: 10.1203/00006450-200003000-00006 – volume: 98 start-page: E1072 issue: 6 year: 2013 ident: 1440_CR29 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-3888 – volume: 12 start-page: 1925 issue: 12 year: 2004 ident: 1440_CR25 publication-title: Obes Res doi: 10.1038/oby.2004.241 – volume: 95 start-page: 4943 issue: 11 year: 2010 ident: 1440_CR16 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2010-0907 – volume: 82 start-page: 107 issue: 2 year: 2000 ident: 1440_CR23 publication-title: Arch Dis Child doi: 10.1136/adc.82.2.107 – volume: 31 start-page: 765 issue: 9 year: 2008 ident: 1440_CR18 publication-title: J Endocrinol Investig doi: 10.1007/BF03349255 – volume: 34 start-page: 917 issue: 11 year: 1997 ident: 1440_CR4 publication-title: J Med Genet doi: 10.1136/jmg.34.11.917 – volume: 65 start-page: 1369 issue: 5 year: 1997 ident: 1440_CR7 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/65.5.1369 – volume: 98 start-page: E328 issue: 2 year: 2013 ident: 1440_CR12 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-2881 – volume: 143 start-page: 372 issue: 3 year: 2003 ident: 1440_CR6 publication-title: J Pediatr doi: 10.1067/S0022-3476(03)00386-X – volume: 94 start-page: 4205 issue: 11 year: 2009 ident: 1440_CR21 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2009-0454 – volume: 97 start-page: 2307 issue: 7 year: 2012 ident: 1440_CR9 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-1182
SSID	ssj0045308
Score	2.3742983
Snippet	Background In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown... In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown that growth... Background In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have shown... Abstract Background In children with Prader-Willi syndrome (PWS), the benefits of growth hormone treatment are well established. Several one-year studies have...
SourceID	doaj pubmedcentral proquest gale crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher
StartPage	1
SubjectTerms	Adults Age Blood pressure Body composition Body fat Body mass Body mass index Care and treatment Children Drug dosages Dual energy X-ray absorptiometry Glucose Growth hormone Growth hormones Human Genetics Insulin Lean body mass Medical research Medicine Medicine & Public Health Pharmacology/Toxicology Physical growth Physiological aspects Prader Willi syndrome Rare diseases Rare endocrinological diseases Somatotropin Studies Young adults Youth
SummonAdditionalLinks	– databaseName: Open Access: DOAJ - Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxFMECjIIiQNETeJXwq0gKjhQVVCk3iw_xt2VqgRtdivtlV-Ox0kWQgVcuMaTh-dhjzOfPxPyQijLCgM8r33V5JwZLBJylQvrS-FtTPKLkA6bUMfH9dlZc_LLUV-ICRvogQfFHYAQ4AqH05TlTHHDfG0KJytVVgUPabVeqGZaTA1jMBesqKctMrU86LE8h_VKBGFhNVPOpqHE1n91TL6Kk_ytWJrmoKPb5NaYPNLD4aPvkGvQ3iU3Po3l8Xvk-2m0DNBt9N6edoGexzX2ekEXMS_tWqA7UDldtnSLYU4T_UZP8W8sPVkhqnlA0NKJyeAN7YctVuDpAPC6BDqCQGjXUtv5LUVc-gj-uk--Hr0_ffchHw9ZyJ0s63VuPXhTAisA6lDymH75GKTOCOmbADJYI4UXEmJmaWtbxatgfRAGggVpHLAHZK-NfXhIqEX6MBbN5QBZ-XkDlQ-SqWitAMBYRspJ59qNDOR4EMaFTiuRWurBTjraSSc7aZmRV7t7vg38G3-Vfoum3Ekid3a6ED1Kjx6l_-VRGXmOjqCRHaNF-M252fS9_vjlsz6UVZzRmeCxLy9HodDFPjgz7maImkBCrZnk_kwyhq-bN0_-psfho9e4Z0fJJqZ-GXm2a8Y7ERLXQrdBmVIxTM_KjKiZn866P29pl4tEIa4Y0izFp7-ePPrny_-s3kf_Q72Pyc0qBaLMK75P9tarDTwh193letmvnqYw_gFMuUuh priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELWgINQL34iFggxC4gARSRw7WW4FUcGBqmoL6s2y4_HuSiipNruV9sovZ8ZxFoUCElzjcWJPZuxJ5s0zYy9kaUVqoEgql0-TQhhKEhZlIq3LpLMY5Kc-HDZRHh5WZ2fTo1gU1g1o9yElGVbq4NaVetNRio1yjgSkooykusqu4XZX0YENxydfh_W3kCKthvKY3_YbbUGBqf_yenwZI_lLojTsPwe3_m_kt9nNGG_y_d5A7rAr0NxlNz7HjPo99v0UXybwDRp8x1vPZ_hZvprzOYaybQN8i0Pni4ZvaGXggbGj4_QDlx8tCQjdg275QH7wlnd9VRY43mPCLoBH3AhvG25bt-EEZY94sfvsy8GH0_cfk3guQ1KrrFol1oEzGYgUoPJZgRGbQ7-ujVRu6kF5a5R0UgEGo7ayOV4F67w04C0oU4N4wHYanMNDxi0xjgmJdgRE5F9MIXdeiTKtlQcQYsKy4VXpOpKW09kZ33T4eKmU7pWrUbk6KFerCXu17XPeU3b8VfodWcBWkui2w4V2OdPRezVIHGJaU6yEIy4LI1xlcIx5meVp4dMJe072o4lQoyHEzsysu05_OjnW-yrHIEDIAufyMgr5FudQm1gAgZogDq6R5N5IEj2-HjcPZqrjitNpKvMp1RSjxQl7tm2mnoSia6Bdk0xWCorosgkrR-Y9mv64pVnMA-t4KYiZCe_-ejDynw__s3of_Zv4Y7abBz9RSV7ssZ3Vcg1P2PX6YrXolk-Dn_8AWeNQeg priority: 102 providerName: Springer Nature
Title	Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition
URI	https://link.springer.com/article/10.1186/s13023-020-01440-6 https://www.proquest.com/docview/2424769283 https://www.proquest.com/docview/2417381241 https://pubmed.ncbi.nlm.nih.gov/PMC7313113 https://doaj.org/article/e55ec0c0110b4374a3d8a0c6271204f0
Volume	15
WOSCitedRecordID	wos000544983900003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Journals customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: RSV dateStart: 20061201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwELZgQ4gXfk8ERmUQEg8QLYkTJ-UFbWgTe1hVdQOVJyuOL20llIymndRX_nLuHKdTmNgLL5USXxo7vjuffZ8_M_YuSbUIcoj9zERDPxY5JQnj1E-0CROjMcgPSnvYRDoaZdPpcOwW3BoHq-x8onXUpi5ojfyAtjGkcoij4efLXz6dGkXZVXeExl22S8dmk56n0-2EK05EkHUbZTJ50FCSjrKWBMWinKbsDUaWs_-mZ76JlvwrZWpHopNH_9uGx-yhi0H5Yas0T9gdqJ6y-2cuy_6M_b7ADga-QSNoeF3yGU7VV3M-x_C2roBvsel8UfENeQtuWTwaTou6fLwkcHQLxOUdIcIn3rQ7tcDwFid2BdxhSXhdcV2bDSd4u8OQPWffTo4vvnz13VkNfiHDbOVrAyYPQQQAWRnGGMUZtPUiT6QZliBLncvEJBIwQNWZjvAuaFMmOZQaZF6A2GM7FbbhBeOaWMhEgroFRO4fDyEypRRpUMgSQAiPhV2nqcIRmdN5Gj-VndBkUrUdrbCjle1oJT32YfvMZUvjcav0EenCVpIouO2NejlTzqIVJFjFoKD4CWucxrkwWY51jNIwCuIy8Nhb0iRFJBsVoXhm-bpp1On5RB3KCAMDkcTYlvdOqKyxDUXuNkXglyBerp7kfk8SvUDRL-5UTjkv1KhrffPYm20xPUnIugrqNcmEqaAoL_RY2lP0XvP7JdVibpnIU0FsTfjvHzuTuH75vz_vy9vr-oo9iKyNSj-K99nOarmG1-xecbVaNMuBtXD7mw3Y7tHxaDwZ2IUUvBqfno1_4NXk_Psfzuhg3g
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCFN2KhgEEgDhA1iRM7i4RQeVRd9aEKFmlvJo4nuyuhpGx2W-2VH8RvZMZJtgoVvfXANZ4ktvN5PM58M8PYi1gZ4acQeYkN-14kUnISRsqLjQ1ia9DI93NXbEIdHCSjUf9wjf1uY2GIVtnqRKeobZnRP_JNCmNQso-74fujnx5VjSLvaltCo4bFLixP8MhWvRt8wu_7Mgy3Pw8_7nhNVQEvk0Ey94wFmwYgfIAkDyK0NyyiMktjafs5yNykMraxBDSlTGJCvArG5nEKuQGZZiDwuZfYZdTjig57arQ64EWx8JM2MCeRmxU5BclLStQv8qHKzubnagSc3QnOsjP_ctG6nW_75v82Z7fYjcbG5lv1orjN1qC4w67uNyyCu-zXEAEMfIk9q3iZ8_GsPJlP-ATN97IAvuLe82nBl6QNuctSUnH6ac0PZ0T-ronGvE348JZXdSQaWF7z4I6BN1wZXhbclHbJib7fcOTusW8XMgP32XqBY3jAuKEsayLGtQNUvCDqQ2hzKZSfyRxAiB4LWpDorEnUTvVCfmh3YEukroGlEVjaAUvLHnu9uueoTlNyrvQHwt5KklKMuwvlbKwbjaUhxi76GdmH2GMVpcImKfYxVEHoR7nfY88JuZqSiBTEUhqni6rSg69f9JYM0fARcYRjedUI5SWOIUuboA-cCco71pHc6Eiilsu6zS3EdaNlK32K7x57tmqmO4k5WEC5IJlACbJigx5TnYXVGX63pZhOXKZ1JSgbFT79TbsET1_-7-l9eH5fn7JrO8P9Pb03ONh9xK6HTj9IL4w22Pp8toDH7Ep2PJ9WsydOu3D2_aKX5h9B8r1Z
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELZgQSsuvBGFBQxC4gDRJvEjKbflUbECqopd0N4sOx63lVCyatKVeuWX43GSQlhAQlzjceJxZpxx5pvPhDwVmWGxBh7lNh1HnGlMEvIsEsYmwhof5McuHDaRTaf5ycl49lMVf0C79ynJtqYBWZrKZv_UutbFc7lfY7oN848IqsLspLxILnEE0uN-_ehLvxZzweK8L5X5bb_B5yiw9p9fm8_jJX9JmoZv0eTa_2txnVzt4lB60BrODXIByptk92OXab9Fvh37lwx04x2hppWjc79dbxZ04UPcqgS6xafTZUk3uGLQwORRU_yxS2crBEi3YFzakyK8pHVbrQWWtlixM6AdnoRWJTWV3VCEuHc4stvk8-Tt8et3UXdeQ1TIJG8iY8HqBFgMkLuE-0jOen8vtJB27EA6o6WwQoIPUk1uUn8VjHVCgzMgdQHsDtkpvQ53CTXIRMaEty9Agn8-htQ6ybK4kA6AsRFJ-temio7MHM_U-KrCpiaXqp1c5SdXhclVckSeb_uctlQef5V-hdawlUQa7nChWs1V59UKhB9iXGAM5Ueccc1srv0Y0yxJY-7iEXmCtqSQaKNEJM9cr-taHR59Ugcy9cEBE9zr8qwTcpXXodBdYYSfCeTmGkjuDST9SlAMm3uTVd1KVCss_8nk2EeRI_J424w9EV1XQrVGmSRjGOklI5INTH2g_rClXC4CG3nGkLHJ3_1Fb_A_Hv7n6b33b-KPyO7szUR9OJy-v0-upMFlZJTyPbLTrNbwgFwuzpplvXoY3P87FqJcQg
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Three+years+of+growth+hormone+treatment+in+young+adults+with+Prader-Willi+syndrome%3A+sustained+positive+effects+on+body+composition&rft.jtitle=Orphanet+journal+of+rare+diseases&rft.au=Damen%2C+Layla&rft.au=Donze%2C+Stephany+H&rft.au=Kuppens%2C+Renske+J&rft.au=Bakker%2C+Nienke+E&rft.date=2020-06-24&rft.pub=Springer+Nature+B.V&rft.eissn=1750-1172&rft.volume=15&rft.spage=1&rft_id=info:doi/10.1186%2Fs13023-020-01440-6
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1172&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1172&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1172&client=summon